OrPro Therapeutics is developing the Theradux^® non-systemic biologic drug platform for treatment of diseases of the lung and other epithelial surfaces characterized by chronic infection, inflammation and obstructive mucus.

In patients with cystic fibrosis, a genetic abnormality causes excessively stiff, viscous mucus that makes simple breathing a challenge and is the underlying cause of impaired lung function and premature death.

OrPro Therapeutics is developing ORP100S, a novel biologic therapy to treat inflammation and obstruction in the lung associated with both chronic airway disorders and progression to severe COVID-19 disease caused by SARS-CoV-2 infection.